ExpreS2ion Biotech: Signs Letter of Intent with WuXi Vaccines
The company has today announced a Letter of Intent (LOI) with WuXi Vaccines, a subsidiary of WuXi Biologics – a leading vaccine Contract Development and Manufacturing Organization (CDMO) – regarding the ExpreS2™ technology platform. The evaluation will be conducted as part of a client project at WuXi and aims to determine whether the platform is suitable for the production of vaccines and other biologics. If the outcome is positive, it may lead to strategic collaboration discussions, potentially resulting in an agreement involving licensing, co-development, co-marketing, or other forms of strategic partnership.
No financial details were disclosed in today’s press release. However, CEO Bent Frandsen commented:
“We are exploring ways to expand the use of ExpreS2™, our recombinant protein production system, to a broader customer base in the vaccine industry. We value our association with WuXi Vaccines, a respected brand in this field, and hope our platform can benefit their clients, thereby supporting ExpreS2ion in promoting our technology.”
The ExpreS2™ platform is included in our valuation model for ExpreS2ion Biotech.
Read the full press release here: LOI with WuXi vaccines
Disclaimer: HC Andersen Capital receives payment from Expre2sion Biotech for a DigitalIR/Corporate Visibility agreement /Claus Thestrup, 15.04.2025, kl. 2:30 PM
ExpreS2ion Biotech Holding
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Read more on company page